It's not that terrifying, there are many drugs approved that are not even more effective than cheaper, older drugs on the market. It takes a wild-scale deployme

It's not that terrifying, there are many drugs approved that are not even more effective than cheaper, older drugs on the market. It takes a wild-scale deployment with 1000's of patients to find rare side effects and to measure the true population-level effectiveness of a drug. This is contrary to the clinical-trial level "efficacy" of a drug, which is with a more limited in terms of N= and in terms of diversity, population. Really, the whole drug approval process is filled with uncertainty. Partly it's how the sausage is made in biotech, but also pharma companies love this method as it allows them to put forward non-inferior drugs with higher margins. We can reform the process, and should, but there will still be statistical uncertainty for 100's of new candidates, until they reach the post-market study phase.